This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nathan's Most Recent Article

A Buysider's Preview of Biotech's Biggest Conference

01/02/13 - 07:00 AM EST

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

read more >

Other Articles by Nathan

Free Reports

Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer

10/15/12 - 06:00 AM EDT

A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.

read more >
Sarepta Shares Still Have Upside

10/03/12 - 10:43 AM EDT

Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.

read more >
Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch

10/01/12 - 07:30 AM EDT

Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302

read more >
A New Reason to be Bullish About Sarepta Therapeutics

09/24/12 - 07:00 AM EDT

A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.

read more >
Idenix Pharma: Guilty By Association

09/21/12 - 07:48 AM EDT

Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.

read more >
Bull Case on Peregrine Pharma Shouldn't Be Dismissed

09/17/12 - 09:33 AM EDT

Believers in Peregrine's lung cancer drug bavituximab state their case.

read more >
Peregrine Pharma: Not Good Enough to Own, Too Risky to Short

09/10/12 - 11:53 AM EDT

Nate Sadeghi examines Peregrine's lung cancer drug bavituximab

read more >
More Reasons to Invest in Sarepta With Caution

08/27/12 - 10:35 AM EDT

Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.

read more >
Sarepta's Risks Shouldn't Be Ignored

08/21/12 - 07:00 AM EDT

There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.

read more >
In These Turbulent Times, Reach for Merck

08/13/12 - 09:03 AM EDT

The company's pipeline could deliver an upside surprise, plus you get a 4% dividend while you wait.

read more >
Page 2 of 5
Top Rated Stocks Top Rated Funds Top Rated ETFs